AR023249A1 - Metodo mejorado de manejo terapeutico de infertilidad mediante la programacion de estimulacion ovarica controlada (cos) y procedimiento de reproduccionasistida (art) - Google Patents

Metodo mejorado de manejo terapeutico de infertilidad mediante la programacion de estimulacion ovarica controlada (cos) y procedimiento de reproduccionasistida (art)

Info

Publication number
AR023249A1
AR023249A1 ARP000101492A ARP000101492A AR023249A1 AR 023249 A1 AR023249 A1 AR 023249A1 AR P000101492 A ARP000101492 A AR P000101492A AR P000101492 A ARP000101492 A AR P000101492A AR 023249 A1 AR023249 A1 AR 023249A1
Authority
AR
Argentina
Prior art keywords
cos
stimulation
programming
art
infertility
Prior art date
Application number
ARP000101492A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of AR023249A1 publication Critical patent/AR023249A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método de manejo terapéutico de infertilidad mediante la programacion de estimulacion ovárica controlada (COS) y procedimientos de reproduccion asistida(ART), las mejoras consisten en: a) la supresion de ovulacion prematura con antagonistas de LHRHe n estimulacion ovárica controlada (COS) y técnicas dereproduccion asistida (ART) con desarrollo de folículos multiples y oocitos; b) programacion del comienzo de la estimulacion ovárica controlada (COS) por mediode la administracion deprogestogenos solos o alternativamente en preparaciones anticonceptivas orales combinadas; c) estimulacion exogena del crecimiento delfolículo en el ovario; d) induccion a la ovulacion con HCG, LHRH natural, agonistas de LHRH o LH recombinante; y e)aplicacion de las técnicas de reproduccionasistida, especialmente IVF, ICSI, GIFT, ZIFT o por inseminacion intrauterina mediante inyeccion de esperma.
ARP000101492A 1999-03-31 2000-03-31 Metodo mejorado de manejo terapeutico de infertilidad mediante la programacion de estimulacion ovarica controlada (cos) y procedimiento de reproduccionasistida (art) AR023249A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12724199P 1999-03-31 1999-03-31
US13163299P 1999-04-28 1999-04-28

Publications (1)

Publication Number Publication Date
AR023249A1 true AR023249A1 (es) 2002-09-04

Family

ID=26825471

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101492A AR023249A1 (es) 1999-03-31 2000-03-31 Metodo mejorado de manejo terapeutico de infertilidad mediante la programacion de estimulacion ovarica controlada (cos) y procedimiento de reproduccionasistida (art)

Country Status (28)

Country Link
US (1) US8173592B1 (es)
EP (1) EP1165138B1 (es)
JP (1) JP4616999B2 (es)
KR (1) KR100679880B1 (es)
CN (1) CN1346281B (es)
AR (1) AR023249A1 (es)
AT (1) ATE265862T1 (es)
AU (1) AU768544B2 (es)
BG (1) BG65270B1 (es)
BR (1) BR0009477A (es)
CA (1) CA2367214C (es)
CO (1) CO4970741A1 (es)
CZ (1) CZ299820B6 (es)
DE (1) DE60010452T2 (es)
DK (1) DK1165138T3 (es)
ES (1) ES2219331T3 (es)
HK (1) HK1044892B (es)
HU (1) HU229252B1 (es)
IL (2) IL145630A0 (es)
MX (1) MXPA01009862A (es)
NO (1) NO327210B1 (es)
NZ (1) NZ514964A (es)
PL (1) PL199569B1 (es)
PT (1) PT1165138E (es)
RU (1) RU2226395C2 (es)
SK (1) SK287244B6 (es)
TW (1) TWI241194B (es)
WO (1) WO2000059542A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A3 (en) 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
RS50428B (sr) 2003-02-21 2009-12-31 Bayer Schering Pharma Aktiengesellschaft, Uv-stabilni transdermalni flasteri
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) * 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
CN101272806A (zh) * 2005-07-22 2008-09-24 武田药品工业株式会社 过早排卵抑制剂
DK2916914T3 (da) * 2012-11-09 2017-01-02 Iasomai Ab N-acetyl-L-cystein til anvendelse i in vitro befrugtning
KR102617137B1 (ko) 2014-09-15 2023-12-27 칠드런'즈 메디컬 센터 코포레이션 히스톤 h3-리신 트리메틸화를 제거함으로써 체세포 핵 이식(scnt) 효율을 증가시키는 방법 및 조성물
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
IL311335A (en) * 2016-09-30 2024-05-01 Sumitomo Pharma Switzerland Gmbh Methods for treating female infertility
RU2665967C1 (ru) * 2017-06-14 2018-09-05 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ стимуляции роста фолликулов в программах экстракорпорального оплодотворения у пациенток с бесплодием различного генеза и "бедным ответом на стимуляцию"
CN107982520A (zh) * 2017-12-25 2018-05-04 上海交通大学医学院附属第九人民医院 外源性MPA与hMG在制备动物模型药物中的应用
CN110570952B (zh) * 2018-06-05 2022-04-12 北京大学第三医院 预测拮抗剂方案下受试者卵巢低反应概率的系统及指导促性腺激素起始用药剂量选择的系统
CN110491505B (zh) * 2019-08-22 2021-06-01 北京大学第三医院（北京大学第三临床医学院） 预测受试者卵巢刺激过程中获得的卵母细胞数量的系统
CN113456801A (zh) * 2021-08-05 2021-10-01 浙江大学医学院附属第四医院 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016259A (en) * 1974-07-26 1977-04-05 Research Corporation Contraceptive polypeptides
JPS6176421A (ja) * 1984-04-03 1986-04-18 セロノ　ラボラトリ−ズ　インコ−ポレイテツド 排卵誘発方法およびインビトロ受精方法
DK0462189T3 (da) 1989-03-10 1995-11-20 Endorecherche Inc Kombinationsterapi til behandling af østrogenfølsomme sygdomme
US5470847A (en) * 1993-12-10 1995-11-28 Board Of Regents, The University Of Texas System Ovulation control by regulating nitric oxide levels with arginine derivatives
WO1996003138A1 (en) 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
EP0788799A3 (en) 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
CA2200541C (en) 1997-01-22 2013-02-19 Philippe Bouchard Lhrh-antagonists in the treatment of fertility disorders
WO1998058647A1 (en) * 1997-06-23 1998-12-30 Mcneil-Ppc Acetaminophen and cisapride analgesics
HU228736B1 (en) * 1998-04-23 2013-05-28 Zentaris Ivf Gmbh Use of lhrh atnagonists in the production of pharmaceutical compostion for the treatment of fertility disorders

Also Published As

Publication number Publication date
NO327210B1 (no) 2009-05-11
HK1044892B (zh) 2011-06-30
DE60010452D1 (de) 2004-06-09
CA2367214A1 (en) 2000-10-12
CN1346281A (zh) 2002-04-24
NO20014736L (no) 2001-11-26
BG65270B1 (bg) 2007-11-30
NZ514964A (en) 2003-08-29
IL145630A0 (en) 2002-06-30
CA2367214C (en) 2008-07-29
PL351327A1 (en) 2003-04-07
KR20010105401A (ko) 2001-11-28
PL199569B1 (pl) 2008-10-31
AU4106900A (en) 2000-10-23
SK287244B6 (sk) 2010-04-07
HK1044892A1 (en) 2002-11-08
SK13842001A3 (sk) 2002-09-10
ATE265862T1 (de) 2004-05-15
IL145630A (en) 2009-09-01
JP4616999B2 (ja) 2011-01-19
BG106045A (en) 2002-05-31
RU2226395C2 (ru) 2004-04-10
MXPA01009862A (es) 2003-10-14
NO20014736D0 (no) 2001-09-28
CN1346281B (zh) 2010-04-14
ES2219331T3 (es) 2004-12-01
US8173592B1 (en) 2012-05-08
PT1165138E (pt) 2004-09-30
HUP0200431A3 (en) 2004-04-28
CO4970741A1 (es) 2000-11-07
TWI241194B (en) 2005-10-11
AU768544B2 (en) 2003-12-18
JP2002541122A (ja) 2002-12-03
CZ299820B6 (cs) 2008-12-03
EP1165138B1 (en) 2004-05-06
HUP0200431A2 (hu) 2002-07-29
HU229252B1 (en) 2013-10-28
KR100679880B1 (ko) 2007-02-07
WO2000059542A1 (en) 2000-10-12
EP1165138A1 (en) 2002-01-02
WO2000059542A9 (en) 2001-11-22
CZ20013495A3 (cs) 2002-06-12
BR0009477A (pt) 2002-01-08
DK1165138T3 (da) 2004-08-30
DE60010452T2 (de) 2005-04-14

Similar Documents

Publication Publication Date Title
AR023249A1 (es) Metodo mejorado de manejo terapeutico de infertilidad mediante la programacion de estimulacion ovarica controlada (cos) y procedimiento de reproduccionasistida (art)
DE3583081D1 (de) In-vitro-fruchtbarkeit.
US6281013B1 (en) Treatment of Infertility
Takahashi et al. GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI–ET with a GnRH agonist protocol
ES2207941T3 (es) Metodo para el tratamiento de trastornos de la fertilidad.
RU2001129500A (ru) Способ терапевтического лечения бесплодия
JP2002541122A5 (es)
WO2004078061A3 (en) Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone
Berg et al. Successful in vitro culture of early cleavage stage embryos recovered from superovulated red deer (Cervus elaphus)
AR037671A1 (es) Uso de leptina o un analogo para la fabricacion de un medicamento para el tratamiento de infertilidad femenina
Felberbaum et al. Are we on the verge of a new era in ART?
Bonacker Development and Evaluation of the 7 & 7 Synch Protocol for Enhanced Control of the Bovine Estrous Cycle among Postpartum Beef Cows
Maurer et al. Cytoskeletal regulation of hCG-induced receptor clustering in transformed leydig cells
Kuczynski et al. INFLUENCE OF COH ON PREVALENCE OF OVARIAN HYPERSTIMULATION SYNDROME
Oktay et al. Continuous combined letrozole-FSH stimulation requires less FSH with similar outcomes compared to standard ovarian stimulation regimens for IVF
Out Henk et al. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization
Fein et al. Subcutaneous (SC) administration of Ferring’s new highly purified, human-derived FSH to female patients participating as egg donors for IVF is an effective and well-tolerated treatment.
RU2001125919A (ru) Лечение бесплодия
UA72513C2 (en) Pharmacological means for treating infertility by programming of controlled ovarian stimulation and assisted reproductive procedures
RU2001125943A (ru) Лечение бесплодия
MXPA00010284A (es) Metodo para el tratamiento de desordenes de la fertilidad
CA2399036A1 (en) Improvement of implantation rate

Legal Events

Date Code Title Description
FC Refusal